Sparfloxacin and levofloxacin were evaluated against 150 Haemophilus influenzae isolates and 149 Neisseria gonorrhoeae isolates in order to define susceptibility testing parameters. Sparfloxacin-susceptible H. influenzae strains were defined as those for which the MICs were 50.25 Fg/ml and the zones were .30 mm, and N. gonorrhoeae susceptible strains were those for which the MICs were 50.03 ,ug/ml and the zones were .39 mm (5-,ug disks). Levofloxacin-susceptible strains ofH. influenzae included those for which the MICs were 50.12 ,ug/ml and the zones were .32 mm and N. gonorrhoeae susceptible strains were those for which the MICs were 50.12 JLg/ml and the zones were .37 mm (5-,g disks MIC control limits were proposed as a result of four separate collaborative studies, each involving five independent laboratories. In two studies, replicate broth microdilution tests were performed with a standard control strain of H. influenzae (ATCC 49247). One study involved tests with sparfloxacin, and the other involved levofloxacin. In both cases, five laboratories each prepared microdilution trays with the study drug diluted in a different lot of HTM broth. A sixth lot of trays was shipped to all participants to provide a common lot control. Each of five laboratories performed 20 separate tests (different inocula) with the set of trays that they prepared and 5 separate tests with the common lot of trays with sparfloxacin or 10 tests with the common lot of trays with levofloxacin. That generated 125 sparfloxacin MICs and 150 levofloxacin MICs. The overall distribution of MICs generated by these exercises was evaluated, and control limits were selected to include MICs 1 doubling dilution interval on either side of the mode.
Sparfloxacin and levofloxacin are fluoroquinolone compounds that are currently being evaluated in a number of clinical trials. Both drugs have broad spectrums of activity, including Haemophilus influenzae and Neisseria gonorrhoeae (2, (5) (6) (7) . In the present report, we document the potencies of both drugs against H. influenzae and propose interpretive criteria for susceptibility tests performed with the Haemophilus Test Medium (HTM) described by Jorgensen et al. (11) . In the same way, we evaluated tests of N. gonorrhoeae using supplemented GC agar (12, 13) in order to select interpretive criteria for agar dilution tests and for disk diffusion tests. In addition, we summarized the results of several multilaboratory studies that were designed to select quality control limits for dilution or disk diffusion tests with standard quality control strains.
MATERIALS AND METHODS
Antimicrobial-susceptibility tests were performed in accordance with the procedures outlined by the National Committee for Clinical Laboratory Standards (12, 13). For testing H. influenzae isolates, broth microdilution and disk diffusion tests were carried out with HTM broth and HTM agar which had been previously screened for proper performance with other antimicrobial agents (4, (12) (13) (14) of GC agar were included, all supplemented with the same lot of XV supplement. Thirty separate inoculum preparations were tested in each laboratory on a unique test lot of agar and on a common lot of GC agar. This exercise generated 300 agar dilution MICs of each study drug. The overall distribution of the 300 MICs was then evaluated to select MIC quality control limits.
Additional collaborative studies were performed to establish zone size control limits for disk diffusion tests. Replicate disk tests were performed with N. gonorrhoeae ATCC 49226 on six different lots of GC agar from one of three manufacturers and with H. influenzae ATCC 49247 on six different lots of HTM agar. In both cases, one of the agar lots was common to all five investigators. Two lots of 5-,ug sparfloxacin disks and two lots of 5-,ug levofloxacin disks were tested each time. Each laboratory tested 30 separate inoculum preparations (20 on the unique lot of agar and 10 on the common lot of agar). This generated 60 zone size determinations by each participant, or a total of 300 zone diameters. The statistic described by Gavan et al. (10) was applied to calculate tentative control limits. That statistic assumes that the median zone for all 300 determinations is the idealized target value and that the extent of acceptable variation on either side of that target value is taken as the median of the five individual laboratory ranges rounded up to the next even value. We also applied an alternative statistic which has been used at the Clinical Microbiology Institute for several years. This uses the all-laboratory mean as the target value, and the range is based on the average of five individual laboratory standard deviations. In both cases, acceptable variability is based on intralaboratory ranges or standard deviations and does not involve interlaboratory variability. Interlaboratory differences influence only the idealized target value; a few aberrant test results in such datum sets influence the means more than the medians.
Correlations between zone diameters and MICs were studied at the Clinical Microbiology Institute. Results from fluoroquinolone compounds were not yet available for testing; all 150 isolates were uniformly susceptible to both study drugs. The MICs of sparfloxacin were <0.125 ,g/ml, and the MICs of levofloxacin were <0.06 ,ug/ml. For reasons that were outlined elsewhere (3), interpretive criteria were selected to describe the susceptible populations. In the absence of resistant or relatively resistant clinical isolates, a resistance category could not be defined. Following the guidelines that we previously used for selecting interpretive breakpoints for other fluoroquinolones (3), proposed sparfloxacin breakpoints are MICs of s0.25 p,g/ml or zones of .30 mm (5-,ug disks) for the susceptible category. For 5-,g levofloxacin disks, susceptible strains were those for which the zones were >32 mm in diameter or the MICs were 0.12 ,ug/ml. In the future, some strains may fail to meet these criteria for susceptibility. Such strains are not necessarily resistant; however, if they do occur, their decreased susceptibility needs to be confirmed by additional in vitro tests, and the patient's response to chemotherapy needs to be documented.
Similar studies were performed with 149 N. gonorrhoeae isolates (Fig. 2) . For gonorrhoeae should be inhibited by <0.03 ,ug of sparfloxacin per ml and that zones around 5-,ug sparfloxacin disks should be 239 mm in diameter. Furthermore, the MICs of levofloxacin should be <0.12 ,g/ml, and zones around 5-,g levofloxacin disks should be 237 mm in diameter. In the future, clinical isolates that perform like our laboratory-selected variants might appear endemically. If they do occur, their responsiveness or lack of responsiveness must be documented before an appropriate interpretive category can be assigned. The interpretive criteria defined above identify only the normal population of gonococci that we now know, and we are assuming that they will be susceptible clinically.
To help standardize methodologic details, quality control parameters must be defined. The reproducibility of broth microdilution MICs with H. influenzae ATCC 49247 is described in Fig. 3 . The all-laboratory modal MICs of sparfloxacin and levofloxacin were 0.008 and 0.016 ,ug/ml, respectively. Vertical dotted lines in Fig. 3 describe proposed control limits which include the mode + 1 doubling dilution interval. All levofloxacin MICs and 91% of the sparfloxacin MICs fell within the proposed control limits. All of the 150 sparfloxacin MICs fell into a 4-dilution range (0.002 to 0.016 ,ug/ml), but the proposed 3-dilution range should reflect more realistic limits for quality control purposes. The results of replicate agar dilution tests with N. gonorrhoeae ATCC 49226 are displayed in Fig. 4 . The all-laboratory mode for both drugs was 0.008 ,g/ml, and the proposed control limits (0.004 to 0.016 ,ug/ml) included all of the 300 levofloxacin MICs and 297 of the 300 sparfloxacin MICs.
Replicate disk diffusion tests with H. influenzae ATCC 49247 were performed in five laboratories. Table 1 describes the results of this exercise. The overall arithmetic mean zone diameter was accepted as the theoretical target value. The average of five individual laboratory standard deviations was accepted as a reasonable extent of intralaboratory variation. The mean + 2x the average standard deviation described the calculated range. The statistic described by Gavan et al. (10) was also applied; the ranges were 1 mm narrower because of the rounding-off process. To avoid excessively stringent control limits for tests on HTM agar, it has been common practice to arbitrarily subtract or add 2 mm at the calculated upper or lower limit, respectively. When that adjustment was arbitrarily applied, the zone size limits for 5-,ug sparfloxacin disks were 33 to 42 mm in diameter, and that included 86% of all of our data (99% were within a range of 31 to 43 mm). For 5-,ug levofloxacin disks, the adjusted limits were 32 to 41 mm, and 94% of our determinations fell within those limits (99% were within a 31-to 42-mm range). For other fluoroquinolone compounds which utilize a 5-,ug disk, approved control limits span an 8-or 9-mm range (14) . The 9-mm ranges proposed for the two study drugs seem to be realistic compromises, even though more stringent limits could be justified statistically and even broader ranges would be needed to include >95% of our collaborative data. 
